NasdaqGS:VRTXBiotechs
Vertex (VRTX) Is Buying Crinetics For $10 Billion To Enter Adrenal Disease
Vertex Pharmaceuticals (NasdaqGS:VRTX) agreed to acquire Crinetics Pharmaceuticals in a US$10b all cash transaction.
The deal brings atumelnant, an advanced clinical stage drug candidate for congenital adrenal hyperplasia, into Vertex's pipeline.
The acquisition marks a move by Vertex into adrenal disease therapeutics, expanding beyond its traditional focus areas.
For investors following Vertex Pharmaceuticals, this deal signals a push beyond the company’s established franchises and into...